Equities

60 Degrees Pharmaceuticals Inc

SXTP:NAQ

60 Degrees Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.9523
  • Today's Change-0.118 / -11.00%
  • Shares traded93.23k
  • 1 Year change-86.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2.140.260.12
Total Receivables, Net0.230.050.15
Total Inventory0.470.520.69
Prepaid expenses4.400.200.23
Other current assets, total00.070
Total current assets7.241.101.18
Property, plant & equipment, net0.070.030.11
Goodwill, net------
Intangibles, net0.230.160.11
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets7.781.301.39
LIABILITIES
Accounts payable------
Accrued expenses0.010.010.05
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.0121--
Other current liabilities, total2.311.820
Total current liabilities2.84240.64
Total long term debt0.151.2719
Total debt0.162319
Deferred income tax------
Minority interest(0.07)(0.57)(0.58)
Other liabilities, total00.260.17
Total liabilities2.912519
SHAREHOLDERS EQUITY
Common stock0.000.004.98
Additional paid-in capital275.160
Retained earnings (accumulated deficit)(33)(29)(23)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.140.070.08
Total equity4.87(24)(18)
Total liabilities & shareholders' equity7.781.301.39
Total common shares outstanding0.480.460.46
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.